These experimental results mimic data from individuals with SMM28,29, which indicates that MAPK–RAS mutations and heterozygous TP53 inactivation accelerate the onset of clinically active MM from precursor conditions. This evidence concerns the gene TP53 and Miyoshi myopathy.